Sustained Antihypertensive Activity of Diltiazem SR: Double‐Blind, Placebo‐Controlled Study with 24‐Hour Ambulatory Blood Pressure Monitoring
Authors:
- 1 September 1992
- journal article
- clinical trial
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 32 (9) , 808-815
Abstract
A new polymeric matrix technology provides a sustained‐release formulation of diltiazem hydrochloride (diltiazem SR) suitable for once‐daily therapy. The efficacy and safety of diltiazem SR were evaluated in a multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study. After a single‐blind, placebo lead‐in period, 275 patients with mild to moderate essential hypertension were assigned to receive placebo or diltiazem SR 120, 240, 360, or 480 mg once daily for 4 weeks. The efficacy evaluation was based on office and 24‐hour ambulatory blood pressure monitoring. Twenty‐four hours after the last dose in the 4‐week, double‐blind treatment period, the mean reduction from baseline in supine diastolic blood pressure ranged from 5.1 to 10.6 mm Hg in the diltiazem SR 120‐to 480‐mg groups, resulting in a significant linear trend across all treatments (P < .001). Reductions in systolic blood pressure were similar. Ambulatory blood pressure monitoring, performed in 138 patients, confirmed the dose‐response relationship and showed consistent antihypertensive activity throughout the 24‐hour dosing interval. The percentage of patients reporting adverse events was similar in the placebo‐ and active‐treated groups. The results of this study indicate that diltiazem SR is well tolerated, lowers blood pressure in a dose‐related manner, and provides sustained activity throughout the 24‐hour dosing interval.Keywords
This publication has 8 references indexed in Scilit:
- Sustained‐Release Diltiazem: Duration of Antihypertensive EffectThe Journal of Clinical Pharmacology, 1989
- Hypertension in Elderly PatientsAnnals of Internal Medicine, 1989
- New insights and new approaches for the treatment of essential hypertension: Selection of therapy based on coronary heart disease risk factor analysis, hemodynamic profiles, quality of life, and subsets of hypertensionAmerican Heart Journal, 1989
- The Relevance of Plasma Lipid Changes with Cardiovascular Drug TherapyMedical Clinics of North America, 1989
- Antihypertensive Drugs and Lipid ProfilesAmerican Journal of Hypertension, 1988
- The 1988 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood PressureArchives of internal medicine (1960), 1988
- Clinical Pharmacokinetics of Verapamil, Nifedipine and DiltiazemClinical Pharmacokinetics, 1986
- Pharmacokinetic and pharmacodynamic effects of diltiazemThe American Journal of Cardiology, 1983